Michelle Graham

This profile gathers the share dealings of Michelle Graham in Albireo Pharma, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 18 January 2022 to 2 March 2023, the count stands at 10 filings.

Every open-market trade on record is a sale: 6 sales worth €93k. Other entries cover 3 share grants. So far in 2023, the count stands at no purchases and 2 sales.

The newest entry dates from 2 March 2023: a transaction, in Albireo Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.